Skip to content

A Prospective Study for the Early Diagnosis of Lung Cancer in Korean Females

A Prospective Study for the Early Diagnosis of Lung Cancer in Korean Females Who Are Never Smoker with a Family History of Lung Cancer

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06181929
Enrollment
200
Registered
2023-12-26
Start date
2024-06-01
Completion date
2034-05-31
Last updated
2025-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Risk Behaviors

Brief summary

This is a single-arm prospective pilot study in a single institution. The target accrual is 200 participants of Korean, female sex, never smoker status, and family history of lung cancer. The study will aim to enroll 200 participants in two years.

Detailed description

Interested individuals will contact a research coordinator who will help to assess for study eligibility. Individuals who are eligible and able to sign informed consent will then proceed to have a LDCT screening exam with a result reported by a radiologist approved to read lung cancer screening scans. Results of this screening test will be discussed with the subject and further recommendations will be given. Negative results will proceed to have repeat LDCT exams for two additional years. Positive results will be recommended to have further diagnostic work-up, and possible treatment. Those with positive findings may be recommended to repeat a LDCT at varied intervals (e.g. at 3 months, at 6 months, etc.) per Lung-RADS recommendations which can be conducted as a research LDCT or as standard-of-care. In addition, blood draw collection for a plasma-based assay will be collected at baseline, first year and second year for all patients along with the repeated LDCT scans. A medical history questionnaire containing questions regarding ethnicity, family history of lung cancer, environmental exposures including secondhand smoke exposure, and a residential district to estimate the exposure of PM2.5 or PM10 will be given to the patient at the initial visit after informed consent has been obtained (Appendix A). Questionnaire can be collected within 1 month from the baseline consent.

Interventions

DIAGNOSTIC_TESTLow dose CT

A subject can voluntarily discontinue active screening with LDCTs after the baseline LDCT is completed but will remain in study follow-up with follow-up calls in 12-month intervals for up to 10 years since initial consent

Sponsors

Sang-Won Um
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

single-arm prospective pilot study

Eligibility

Sex/Gender
FEMALE
Age
45 Years to 74 Years
Healthy volunteers
Yes

Inclusion criteria

1. Age 45-74 years old 2. Korean female 3. Never smoker defined as a lifetime exposure of less than 100 cigarettes 4. Family history of lung cancer at first degree relatives (parents, siblings, or children)

Exclusion criteria

1. Prior history of lung cancer. 2. Diagnosis of any cancer within the past five years 3. Participation in a cancer prevention trial. 4. Present symptoms suggestive of current lung cancer, including: unexplained weight loss of over 5 kilograms within the last 12 months or unexplained hemoptysis. 5. Medical or psychiatric condition precluding informed medical consent. 6. History of LDCT screening, chest CT, PET or PET/CT scan within 10 years

Design outcomes

Primary

MeasureTime frameDescription
Lung cancer detection rateup to 2yearsdetection rate

Secondary

MeasureTime frameDescription
incidence of lung cancerup to 2yearsWhether lung cancer is found in each screening test conducted for the first (baseline) and first and second years
distribution of lung cancer stagesup to 2yearsnumber of lung cancer diagnosed, number of stage I, rate of surgery, rate of false positive
Estimation of the Early Detection Rate of Lung Cancer in Liquid Biopsyup to 2yearscfDNA

Other

MeasureTime frameDescription
identification of potential predictive biomarkers of malignancyup to 2yearsEGFR mutation

Countries

South Korea

Contacts

Primary ContactUm Sang-Won, PhD
sangwonum72@gmail.com82-2-3410-1645
Backup ContactKyungmi Park
gyeong.mi@sbri.co.kr82-2-2008-0429

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026